ArticleFrontiers in endocrinology2022
Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model.
Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 55 citations in OpenAlex.
- Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.iScience · 2026Article
- Comparative risk of hepatocellular carcinoma and mortality among initiators of GLP-1 receptor agonists versus other glucose-lowering therapies: a target trial emulation.Hepatology international · 2026Article
- Semaglutide treatment in MOSH is associated with altered DNA methylation patterns of genes related to glycolipid metabolism.Scientific reports · 2026Article
- Perinatal Semaglutide Treatment Improves Maternal Health and Mitigates Offspring Metabolic Dysfunction in a Mouse Model of Maternal Obesity.bioRxiv : the preprint server for biology · 2026Article
- Sex-Specific and Reproductive Status-Dependent Effects of Liraglutide on Metabolic Disorders Associated with Prediabetes.Antioxidants (Basel, Switzerland) · 2026Article
- EDL6D, a bioactive peptide phenocopying SHBG-associated metabolic effects: a new preclinical lead compound for treating the metabolic dysfunction-associated fatty liver disease.Journal of translational medicine · 2026Article
- 9.4-T MRI monitoring of early MASH progression and therapeutic response in a prefibrotic mouse model.European radiology experimental · 2026Article
- Phyllanthus niruri niosomes ameliorate obesity-induced hepatic steatosis in rats via modulating MALAT1/miR-206/GLP-1R signaling and hepatic lipid metabolism.Biological research · 2026Article
- The Interplay Between GLP-1-Based Therapies, the Gut Microbiome, and MASLD/MASH in Type 2 Diabetes Mellitus: A Narrative Review.Biomedicines · 2026Review
- Development of NAFLD-Specific Human Liver Organoid Models on a Microengineered Array Chip for Semaglutide Efficacy Evaluation.Cell proliferation · 2026Article
- Mazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Alleviating Inflammation.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Repurposing of semaglutide by targeting SIRT1 and TGF-β/Smad signaling in hepatic fibrosis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Divergent effects of semaglutide and CRV431 Co-therapy on liver fibrosis and HCC in MASLD mouse model.PloS one · 2026Article
- Multi-pathway-driven hepatic protection: Semaglutide combined with HIIT counteracts diabetic liver injury in db/db mice.Journal of diabetes investigation · 2025Article
- The expanding role of semaglutide: beyond glycemic control.Journal of diabetes and metabolic disorders · 2025Review
- The impact of semaglutide on liver outcomes in patients with or at risk of MASH: a dose and duration response meta-analysis of randomized trials.Diabetology & metabolic syndrome · 2025Review
- Semaglutide Exacerbates Stunting in Growth-Impaired Juvenile Male Mice via Reduced Energy Metabolism.Journal of the Endocrine Society · 2025Article
- Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- Metabolic and hepatic effects of semaglutide and empagliflozin on metabolic dysfunction-associated steatotic liver disease mice.World journal of hepatology · 2025Article
- Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review.World journal of gastroenterology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The aim of this study was to evaluate changes in body weight, liver weight, blood glucose, liver injury markers, pro-inflammatory factors and oxidative stress marker levels in obese mice with HFD induced NAFLD after semaglutide use. Patients and methods: The 24 C57BL6J mice were randomly divided into three groups (NCD, HFD and Sema) for the assessment of metabolic status, inflammatory factor and oxidative stress marker levels, liver histopathology in mice. Liver metabolomics was determined by liquid chromatography/mass spectrometry (LC-MS) method. Results: The mice body weight, liver weight, blood glucose, TG, TCHO, LDL and pro-inflammatory factors were significantly reduced after semaglutide. Meanwhile, semaglutide increased the SOD level. Semaglutide treatment significantly improved the pathological changes such as hepatocyte steatosis, balloon degeneration and lymphoid foci by HE. It also significantly reduced lipid droplet by Oil Red O. The mitochondria were swollen, the volume increased, the cristae were partially broken and reduced, the intramembrane matrix was partially dissolved, and the mitophagy structure was visible in the visual field. There were 6 metabolites down-regulated and 2 metabolites significantly up-regulated after semaglutide treatment. Conclusions: Semaglutide can reduce blood glucose level and liver fat accumulation and play an anti-inflammatory role in advanced NAFLD that due to the effects of HFD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.